Literature DB >> 15063205

Synthesis of a 6(V)-sulfated mannopentasaccharide analogue related to PI-88.

Guofeng Gu1, Guohua Wei, Yuguo Du.   

Abstract

An efficient and convergent synthesis of a regioselectively 6(V)-sulfated mannopentasaccharide derivative 1c, octyl 6-O-sulfo-alpha-D-mannopyranosyl-(1-->3)-alpha-D-mannopyranosyl-(1-->3)-alpha-d-mannopyranosyl-(1-->3)-alpha-D-mannopyranosyl-(1-->2)-alpha-D-mannopyranoside, was achieved by a '3 + 2' strategy. The target was designed to mimic the promising anticancer agent PI-88 and was obtained from the building blocks, octyl 3,4,6-tri-O-benzoyl-alpha-D-mannopyranoside, allyl 2,4,6-tri-O-benzoyl-3-O-(4-methoxybenzyl)-alpha-D-mannopyranoside, and 6-O-acetyl-2,3,4-tri-O-benzoyl-alpha-D-mannopyranosyl trichloroacetimidate (11), under TMSOTf-catalyzed glycosylation conditions. Compound 1c displays a mild anti-angiogenic activity based on a chorioallantoic membrane (CAM) model study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063205     DOI: 10.1016/j.carres.2004.01.020

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  3 in total

1.  Inhibitors of slit protein interactions with the heparan sulphate proteoglycan glypican-1: potential agents for the treatment of spinal cord injury.

Authors:  Elizabeth Lau; Richard U Margolis
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-10-16       Impact factor: 2.557

2.  A Concise Synthesis of a BODIPY-Labeled Tetrasaccharide Related to the Antitumor PI-88.

Authors:  Juan Ventura; Clara Uriel; Ana M Gomez; Edurne Avellanal-Zaballa; Jorge Bañuelos; Inmaculada García-Moreno; Jose Cristobal Lopez
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

3.  Synthesis of a pseudo-disaccharide library and its application to the characterisation of the heparanase catalytic site.

Authors:  Victoria Vinader; Mohamed H Haji-Abdullahi; L H Patterson; Kamyar Afarinkia
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.